🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I am so proud of Misty Evans the BMTCN of the Year. Well deserved!! ONCC Sarah Cannon Docs

Excited to attend the 4th Global Congress on Sickle Cell Disease in Paris. Global Sickle Cell Disease Network #GCSCD2022

It is amazing to see how our teams work using CRISPR Cas9 gene editing have impacted the lives of patients with sickle cell disease. bostonglobe.com/2022/06/28/bus…

So close to funding a pediatric YIA tonight ! Just a few more dollars to reach our goal ❤️ A truly great cause — text to 4114 Pediatric Oncology or conquer.org/PEDIATRIC22

Very excited to participate in the #pm22hms at DBMI at Harvard Med. Looking forward to a lively discussion!

IACH last webinar of the year 2022 dedicated to gene therapy in hemoglobinopathies. Thank you Dr Haydar Frangoul for a fantastic and timely overview post #ASH22 @SelimCorbaciog1 Sickle Cell Society Thalassemia Canada

Sarah Cannon Transplant and Cellular Therapy Program Methodist Hospital San Antonio Texas is celebrating 30 years of transplant care serving the people of Central and South Texas. Hosting our 10th annual ASH review Feb 4th 8am to 1pm

I am so happy for Victoria Gray who gave such an inspiring talk at the Third International Summit on Human Gene Editing in London ⁦The Royal Society⁩

Great presentation by Rabi Hanna reporting the initial results of EDIT-301 at #EHA2023 #Frankfurt

Exceptional #efficacy and #durable response #exacel in #TDT & #SickleCell #EHA23 European Hematology Association #Frankfurt, grateful Imperial Department of Immunology & Inflammation Centre for Paediatrics & Child Health Imperial NHS 💙 part of this work

HCA Healthcare patient Jimi is giving hope to those living with #SickleCellDisease by participating in an innovative clinical trial with Sarah Cannon Docs exploring the use of #CRISPR gene editing. Learn about its potential impact in The Washington Post: bit.ly/3YFq1b2.

📢 We’ve authorised a new treatment for sickle-cell disease and transfusion-dependent β-thalassemia for patients aged 12 and over, after rigorous assessment of its safety, quality, and effectiveness. 📢 Read more here 🔗 bit.ly/3stHAz8

fda.gov/news-events/pr…

So proud of our team at SCRI and TriStar Children Hospital to be part of this transformational therapy for people with SCD fda.gov/news-events/pr…

Another huge milestone for gene editing in hemoglobinopathies with the FDA approval of Casgevy for Transfusion Dependent Beta Thalassemia. Proud of our team who played a part in making this happen. #CRISPR-Cas9 #Geneediting #Casgevy fda.gov/news-events/pr…

Of 30 patients with severe #SickleCellDisease who were treated with gene-edited autologous hematopoietic stem and progenitor cells, 29 were free from vaso-occlusive crises for at least 12 consecutive months. Read the full CLIMB SCD-121 study results: nej.md/3UvzPDT

Thank you to all the patients and families that participated in this pivotal trial. Very proud of our team to be part of making this transformative therapy available to individuals with SCD. nejm.org/doi/full/10.10…

The invasion has started. Frangoul yard today. #cicadas

Interesting that a study in adult patients have equivalent if not better results than the high risk Peds trials. Very impressive!!! Time to add Blina to Peds upfront therapy.